Pharmaceutical Technology

APRIL 13, 2023

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. Bluebird already uses a lentiviral vector in its approved gene therapy for beta-thalassemia called Zynteglo. Also known as lovo-cel, bluebird bio’s product is a lentiviral gene therapy.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

pharmaphorum

APRIL 14, 2022

million price tag. The FDA is currently reviewing beti-cel – also known as Zynteglo (betibeglogene autotemcel) – as a treatment for patients with beta thalassaemia who require regular blood transfusions.

Gene Therapy 62

Gene Therapy Gene Marketing Clinical Trials 62

pharmaphorum

JUNE 12, 2022

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 million price tag, saying its ability to help patients reach sustained transfusion independence justified its high price. Beti-cel offers another potentially curative treatment for a much broader range of patients.

Gene Therapy 57

Gene Therapy Gene Marketing Trials 57

pharmaphorum

JANUARY 11, 2021

Zynteglo is already in beta-thalassemia in Europe, where the company will seek to expand access despite its hefty $1.8 million price tag. The gene therapy firm will be focused on its most important therapies in beta-thalassemia, cerebral adrenoleukodystrophy and sickle cell disease in the US And Europe.

Gene Therapy 59

Gene Therapy Gene Genetic Disease Manufacturing 59

Drug Discovery World

MAY 22, 2023

But are these price tags a barrier to access? Simply, yes, as we saw when the European Commission rejected the price point for bluebird bio’s Zynteglo. The cost 2022 has not been shy of approvals – Uniqure and CSL’s Haemophilia B drug even nabbed the title of “Most Expensive Drug” at $3.5 million per dose.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

XTalks

AUGUST 19, 2022

Bluebird bio’s gene therapy Zynteglo (betibeglogene autotemcel, beti-cel) has been awarded a much anticipated approval from the US Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with beta thalassemia who need regular blood transfusions. Zynteglo’s hefty price tag of $2.8

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

XTalks

SEPTEMBER 27, 2022

The drug took over the world’s most expensive drug title from fellow bluebird bio gene therapy Zynteglo, which received FDA approval last month, by just a couple of hundred grand as Zynteglo costs $2.8 Gene Therapy Zynteglo Wins Landmark FDA Approval for Beta Thalassemia. Related: Bluebird’s $2.8M

FDA Approval 52

FDA Approval Gene Therapy Drugs Gene 52

pharmaphorum

FEBRUARY 16, 2021

It’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its beta thalassaemia gene therapy Zynteglo for regular NHS use in first draft guidance. million in Europe. NICE said that data came from a small sample of patients and is using its standard discount rate of 3.5%

Gene Therapy 75

Gene Therapy Gene Medicine Development 75

pharmaphorum

NOVEMBER 16, 2022

Only a few years later, bluebird bio’s gene therapy, Zynteglo (betibeglogene autotemcel), was approved in the European market for the treatment of the rare blood disorder, beta thalassaemia. However, with a price tag of €1.58 At more than $2.1 The post Advanced therapies and the high-profile pricing dilemma appeared first on.

Gene Therapy 130

Gene Therapy Gene Marketing Development 130

pharmaphorum

AUGUST 26, 2022

BioMarin will no doubt have an eye on the earlier experience of bluebird bio, which secured EU approval for rare disease gene therapy Zynteglo (betibeglogene autotemcel) in 2019 for beta thalassaemia with a price tag of around €1.6 million spread over five years.

Gene Therapy 109

Gene Therapy Gene Antibody Marketing 109

XTalks

DECEMBER 21, 2022

Zynteglo (betibeglogene autotemce) for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell (RBC) transfusions. Bluebird bio is a notable mention as it secured FDA approvals for two of its gene therapies, Zynteglo and Skysona. Manufacturer: bluebird bio, Inc. million for a single infusion.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

XTalks

FEBRUARY 27, 2024

bluebird won approvals for two other gene therapies in 2022 — Skysona (elivaldogene autotemcel, eli-cel) for the treatment of the rare neurological disorder cerebral adrenoleukodystrophy (CALD) and Zynteglo (betibeglogene autotemcel, beti-cel) for beta-thalassemia.

Research 59

Research Drugs Gene Therapy Clinical Trials 59